The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis
Abstract
Computational modeling of the ErbB signaling network affirms ErbB3 as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Schoeberl, B., Eichler-Jonsson, C., Gilles, E. D., & Müller, G. (2002) · Nature Biotechnology · doi:10.1038/nbt0402-370 · Cited by 950
Self-citationTargeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Endocytosis and intracellular trafficking of ErbBs
Sorkin, A., & Goh, L. K. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.029 · Cited by 756
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 626
Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor
Kholodenko, B. N., Demin, O. V., Moehren, G., & Hoek, J. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30169 · Cited by 618
The ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608
Rapid Generation of Single-Tumor Spheroids for High-Throughput Cell Function and Toxicity Analysis
Ivascu, A., & Kubbies, M. (2006) · SLAS Discovery · doi:10.1177/1087057106292763 · Cited by 597
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
Citri, A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00101-5 · Cited by 595
Physicochemical modelling of cell signalling pathways
Aldridge, B. B., Burke, J. M., Lauffenburger, D. A., & Sorger, P. K. (2006) · Nature Cell Biology · doi:10.1038/ncb1497 · Cited by 592
Clark, A. S., West, K. A., Streicher, S. A., & Dennis, P. A. (2002) · PubMed · Cited by 589
Self-citationSystems biology and combination therapy in the quest for clinical efficacy
Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio817 · Cited by 570
Self-citationCutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 401
The EGF receptor family: spearheading a merger of signaling and therapeutics
Bublil, E. M., & Yarden, Y. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.008 · Cited by 397
Chen, W. W., Schoeberl, B., Jasper, P. J., Niepel, M., Nielsen, U. B., Lauffenburger, D. A., & Sorger, P. K. (2009) · Molecular Systems Biology · doi:10.1038/msb.2008.74 · Cited by 391
Self-citationBinding specificities and affinities of egf domains for ErbB receptors
Jones, J. T., Akita, R. W., & Sliwkowski, M. X. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00283-5 · Cited by 381
Trafficking of the ErbB receptors and its influence on signaling
Wiley, H. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00002-8 · Cited by 348
Britsch, S., Li, L., Kirchhoff, S., Theuring, F., Brinkmann, V., Birchmeier, C., & Riethmacher, D. (1998) · Genes & Development · doi:10.1101/gad.12.12.1825 · Cited by 344
Adams, C. W., Allison, D. E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K., & Sliwkowski, M. X. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316
Beerli, R. R., & Hynes, N. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.6071 · Cited by 308
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Wiley, H. S., Herbst, J. J., Walsh, B. J., Lauffenburger, D. A., Rosenfeld, M. G., & Gill, G. N. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99131-3 · Cited by 287
van Riel, N. A. W. (2006) · Briefings in Bioinformatics · doi:10.1093/bib/bbl040 · Cited by 254
Wong, S.-F. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.003 · Cited by 249
Ligand‐dependent responses of the ErbB signaling network: experimental and modeling analyses
Birtwistle, M. R., Hatakeyama, M., Yumoto, N., Ogunnaike, B. A., Hoek, J. B., & Kholodenko, B. N. (2007) · Molecular Systems Biology · doi:10.1038/msb4100188 · Cited by 234
HATAKEYAMA, M., KIMURA, S., NAKA, T., KAWASAKI, T., YUMOTO, N., ICHIKAWA, M., KIM, J.-H., SAITO, K., SAEKI, M., SHIROUZU, M., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021824 · Cited by 233
Riese, D. J., Bermingham, Y., van Raaij, T. M., Buckley, S., Plowman, G. D., & Stern, D. F. (1996) · PubMed · Cited by 228
Her2-positive breast cancer: Herceptin and beyond
Dean-Colomb, W., & Esteva, F. J. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.013 · Cited by 208
Control of MAPK signalling: from complexity to what really matters
Hornberg, J. J., Binder, B., Bruggeman, F. J., Schoeberl, B., Heinrich, R., & Westerhoff, H. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208817 · Cited by 199
Self-citationExpression of the c-erbB-3 protein in normal human adult and fetal tissues.
Prigent, S. A., Lemoine, N. R., Hughes, C., Plowman, G. D., Selden, C., & Gullick, W. (1992) · PubMed · Cited by 182
Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells
Liu, B., Ordonez‐Ercan, D., Fan, Z., Edgerton, S. M., Yang, X., & Thor, A. D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22423 · Cited by 160
Liscovitch, M., & Ravid, D. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.01.013 · Cited by 152
Autocrine loops with positive feedback enable context-dependent cell signaling
Shvartsman, S. Y., Hagan, M. P., Yacoub, A., Dent, P., Wiley, H. S., & Lauffenburger, D. A. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00260.2001 · Cited by 138
Kim, W. B., Moon, S.-O., Sung, M. J., Kim, S. H., Lee, S., So, J.-N., & Park, S. K. (2003) · The FASEB Journal · doi:10.1096/fj.02-1209fje · Cited by 136
Alimandi, M., Wang, L., Bottaro, D. P., Lee, C., Kuo, A. H., Frankel, M. E., Fedi, P., Tang, C. K., Lippman, M. E., & Pierce, J. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5608 · Cited by 132
Structure-function and biological role of betacellulin
Dunbar, A. J., & Goddard, C. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(00)00028-5 · Cited by 119
Atlas, E., Cardillo, M., Mehmi, I., Zahedkargaran, H., Tang, C. K., & Lupu, R. (2003) · PubMed · Cited by 113
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes, E. E., & Chu, E. (2006) · PubMed · Cited by 106
Pinkas‐Kramarski, R., Lenferink, A. E. G., Bacus, S. S., Lyass, L., van de Poll, M. L. M., Klapper, L. N., Tzahar, E., Sela, M., van Zoelen, E. J. J., & Yarden, Y. (1998) · Oncogene · doi:10.1038/sj.onc.1201642 · Cited by 99
ErbB3-Dependent Motility and Intravasation in Breast Cancer Metastasis
Xue, C., Liang, F., Mahmood, R., Vuolo, M. A., Wyckoff, J. B., Qian, H., Tsai, K.-L., Kim, M., Locker, J. D., Zhang, Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0550 · Cited by 97
Sakai, K., Yokote, H., Murakami‐Murofushi, K., Tamura, T., Saijo, N., & Nishio, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00553.x · Cited by 96
Role of heregulin in human cancer
Breuleux, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7120-0 · Cited by 88
Smith, B. L., Chin, D., Maltzman, W., Crosby, K., Hortobágyi, G. N., & Bacus, S. S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602090 · Cited by 85
Hamburger, A. W. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9077-5 · Cited by 84
Screening for Compounds That Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids
Herrmann, R., Fayad, W., Schwarz, S., Berndtsson, M., & Linder, S. T. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107310442 · Cited by 84
The initiation of colon cancer in a chronic inflammatory setting
Chen, R., Rabinovitch, P. S., Crispin, D. A., Emond, M. J., Bronner, M. P., & Brentnall, T. A. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi106 · Cited by 69
Kim, H. S., Shin, H. S., Kwak, H. J., Cho, C., Lee, C. O., & Koh, G. Y. (2002) · The FASEB Journal · doi:10.1096/fj.02-0570fje · Cited by 66
Transcriptomic analysis of the NCI-60 cancer cell lines
Weinstein, J. N., & Pommier, Y. G. (2003) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2003.08.005 · Cited by 63
Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer
Xing, H., Cordon‐Cardo, C., Deng, X., Tong, W. P., Campodonico, L., FUKS, Z. Y., & Kolesnick, R. N. (2003) · Nature Medicine · doi:10.1038/nm927 · Cited by 56
van der Horst, E. H., Murgia, M., Treder, M., & Ullrich, A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20867 · Cited by 56
Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm
Boerner, J. L. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00096-4 · Cited by 52
Folgiero, V., Avetrani, P., Bon, G., Carlo, S. E. D., Fabi, A., Nisticò, C., Vici, P., Melucci, E., Buglioni, S., Perracchio, L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001592 · Cited by 51
Hendriks, B. S., Cook, J., Burke, J. M., Beusmans, J. M., Lauffenburger, D. A., & de Graaf, D. (2006) · Systems Biology · doi:10.1049/ip-syb:20050057 · Cited by 39
Isolation of scFvs to In Vitro Produced Extracellular Domains of EGFR Family Members
Horak, E. M., Heitner, T., Robinson, M. K., Simmons, H. H., Garrison, J. L., Russeva, M., Furmanova, P., Lou, J., Zhou, Y., Yuan, Q., et al. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.603 · Cited by 34
Systems-Level Analysis of ErbB4 Signaling in Breast Cancer: A Laboratory to Clinical Perspective
Chuu, C., Chen, R.-Y., Barkinge, J. L., Ciaccio, M. F., & Jones, R. B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0369 · Cited by 29
Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer
von Eyben, F. E. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600728369 · Cited by 19
Using computational modeling to drive the development of targeted therapeutics.
Nielsen, U. B., & Schoeberl, B. (2005) · PubMed · Cited by 16
Self-citationTargeting ERBB Receptors in Cancer
Hynes, N. E. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_4 · Cited by 11
Cited by
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Monoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Cancer systems biology: a network modeling perspective
Kreeger, P. K., & Lauffenburger, D. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp261 · Cited by 368
Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341
Metadata
- Authors
- Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., Grantcharova, V., Kohli, N., West, K. A., Leszczyniecka, M., Feldhaus, M. J., Kudla, A. J., & Nielsen, U. B.
- Venue
- Science Signaling
- Published
- 2009-06-30
- Volume
- 2
- Issue
- 77
- Pages
- ra31-ra31
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W1979056373
- Cited by
- 360
- References
- 69
- FWCI
- 14.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.